4D Molecular Therapeutics/$FDMT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About 4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Ticker
$FDMT
Sector
Primary listing
Employees
227
Headquarters
FDMT Metrics
BasicAdvanced
$416M
-
-$3.52
2.85
-
Price and volume
Market cap
$416M
Beta
2.85
52-week high
$10.03
52-week low
$2.24
Average daily volume
653K
Financial strength
Current ratio
8.746
Quick ratio
8.456
Long term debt to equity
4.124
Total debt to equity
5.483
Profitability
EBITDA (TTM)
-215.823
Gross margin (TTM)
-515,724.24%
Net profit margin (TTM)
-594,375.76%
Operating margin (TTM)
-667,654.55%
Management effectiveness
Return on assets (TTM)
-25.18%
Return on equity (TTM)
-38.87%
Valuation
Price to revenue (TTM)
15,033.784
Price to book
0.99
Price to tangible book (TTM)
0.99
Price to free cash flow (TTM)
-2.92
Free cash flow yield (TTM)
-34.24%
Free cash flow per share (TTM)
-3.047
Growth
Revenue change (TTM)
-99.84%
Earnings per share change (TTM)
51.71%
3-year revenue growth (CAGR)
-77.35%
3-year earnings per share growth (CAGR)
1.78%
What the Analysts think about FDMT
Analyst ratings (Buy, Hold, Sell) for 4D Molecular Therapeutics stock.
Bulls say / Bears say
4D Molecular Therapeutics reported a net loss of $48.0 million for Q1 2025, up from $32.4 million in Q1 2024, representing a 48% year-over-year widening of its losses. (Reuters)
Research and development expenses rose sharply to $40.7 million in Q1 2025 from $27.9 million in Q1 2024, largely due to the initiation of the first Phase 3 trial of 4D-150, increasing cash burn risk. (Reuters)
Cash, cash equivalents, and marketable securities fell to $458 million as of March 31, 2025 from $505 million at the end of 2024, indicating significant operational cash burn during the quarter. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
FDMT Financial Performance
Revenues and expenses
FDMT Earnings Performance
Company profitability
FDMT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for 4D Molecular Therapeutics stock?
4D Molecular Therapeutics (FDMT) has a market cap of $416M as of October 12, 2025.
What is the P/E ratio for 4D Molecular Therapeutics stock?
The price to earnings (P/E) ratio for 4D Molecular Therapeutics (FDMT) stock is 0 as of October 12, 2025.
Does 4D Molecular Therapeutics stock pay dividends?
No, 4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next 4D Molecular Therapeutics dividend payment date?
4D Molecular Therapeutics (FDMT) stock does not pay dividends to its shareholders.
What is the beta indicator for 4D Molecular Therapeutics?
4D Molecular Therapeutics (FDMT) has a beta rating of 2.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.